Paclitaxel/Taxol / ChemoSen Cancer Research Results

PacT, Paclitaxel/Taxol: Click to Expand ⟱
Features:
Paclitaxel (brand name Taxol) is a chemotherapy medication used to treat ovarian cancer, esophageal cancer, breast cancer, lung cancer, Kaposi's sarcoma, cervical cancer, and pancreatic cancer. Administered by intravenous injection.
Derived from a natural product, Taxol (from Pacific Yew Tree).
Paclitaxel is a drug (chemotherapy; a taxane). Its dominant anticancer mechanism is microtubule stabilization, which disrupts normal mitosis and drives mitotic arrest/stress signaling that can culminate in apoptosis.


Paclitaxel – Cancer Pathway Matrix

Rank Pathway / Axis Cancer / Tumor Context Normal Tissue Context TSF Primary Effect Notes / Interpretation
1 Microtubule stabilization → Mitotic arrest Mitotic progression ↓; spindle dynamics impaired; cell division blocked Proliferating normal cells affected R, G Core cytotoxic mechanism Binds β-tubulin and stabilizes microtubules, preventing normal depolymerization required for mitosis.
2 Spindle assembly checkpoint activation Prolonged mitotic arrest → mitotic catastrophe or apoptosis Checkpoint stress in dividing tissues R, G Mitotic stress execution Cell fate depends on whether arrest resolves via apoptosis or mitotic slippage.
3 Intrinsic apoptosis (mitochondrial pathway) Caspase activation ↑; BAX/mitochondrial signaling engaged (context) Limited unless stressed G Cell death execution Often downstream of prolonged mitotic stress and mitochondrial perturbation.
4 ROS generation (secondary) ROS ↑ (context-dependent); oxidative stress amplification Oxidative stress possible in sensitive tissues R, G Stress amplifier ROS rise appears secondary to mitotic and mitochondrial dysfunction; may enhance apoptosis.
5 Nrf2 antioxidant response (adaptive) Nrf2 ↑ in some tumors; antioxidant buffering ↑; resistance potential Protective antioxidant signaling G Adaptive resistance axis Not a direct paclitaxel target; elevated Nrf2 may reduce drug sensitivity.
6 Drug resistance mechanisms P-glycoprotein (MDR1) ↑; β-tubulin alterations; survival rewiring — G Treatment failure driver Efflux pumps and tubulin adaptations are major clinical resistance mechanisms.
7 Myelosuppression — Neutropenia risk ↑ G Dose-limiting toxicity Bone marrow suppression is a primary clinical constraint.
8 Peripheral neuropathy — Sensory neuropathy risk ↑ G Dose-limiting toxicity Likely related to microtubule disruption in axonal transport.

Time-Scale Flag (TSF):
P = 0–30 min (drug binding begins)
R = 30 min–3 hr (mitotic stress signaling, ROS changes)
G = >3 hr (apoptosis, resistance adaptation, tissue toxicities)



ChemoSen, chemo-sensitization: Click to Expand ⟱
Source:
Type:
The effectiveness of chemotherapy by increasing cancer cell sensitivity to the drugs used to treat them, which is known as “chemo-sensitization”.

Possible Chemo-Sensitizers:
-Curcumin
-Resveratrol
-EGCG
-Quercetin
-Genistein
-Berberine
-Piperine: alkaloid from black pepper
-Ginsenosides: active components of ginseng
-Silymarin
-Allicin
-Lycopene
-Ellagic acid
-Caffeic acid phenethyl ester
-flavopiridol
-oleandrin
-Ursolic acid
-butein
-Betulinic acid
Scientific Papers found: Click to Expand⟱
1325- EMD,  PacT,    Emodin enhances antitumor effect of paclitaxel on human non-small-cell lung cancer cells in vitro and in vivo
- vitro+vivo, Lung, A549
TumCP↓, Apoptosis↑, BAX↑, Casp3↑, Bcl-2↓, p‑Akt↓, p‑ERK↓, ChemoSideEff∅, ChemoSen↑,
6972- Form,  PacT,    Formononetin ameliorates the drug resistance of Taxol resistant triple negative breast cancer by inhibiting autophagy
- in-vivo, BC, MDA-MB-231
AntiCan↑, miR-199↓, ChemoSen↑, TumVol↓, Dose↝, TumCG↓, TumCCA↑, Apoptosis↑, TumAuto↓, eff↓,
805- GAR,  Cisplatin,  PacT,    Garcinol Exhibits Anti-Neoplastic Effects by Targeting Diverse Oncogenic Factors in Tumor Cells
- Review, NA, NA
ERK↓, PI3K/Akt↓, Wnt/(β-catenin)↓, STAT3↓, NF-kB↓, ChemoSen↑, COX2/PTGS2↓, Casp3↑, Casp9↑, BAX↑, Bcl-2↓, VEGF↓, TGF-β↓, HATs↓, E-cadherin↑, Vim↓, Zeb1↓, ZEB2↓, Let-7↑, MMP9↓, TumCCA↑, ROS↑, MMP↓, IL6↓, NOTCH1↓, antiNeop↑,
7568- HYP,  PacT,    Administration with hyperoside sensitizes breast cancer cells to paclitaxel by blocking the TLR4 signaling
- in-vitro, BC, MDA-MB-231
Inflam↓, AntiTum↑, selectivity↑, chemoP↑, TumCI↓, ChemoSen↑, tumCV↓, Apoptosis↑, Casp3↑, TLR4↓, NF-kB↓,
7713- IP6,  PacT,    Inositol hexaphosphate and paclitaxel: symbiotic treatment of oral cavity squamous cell carcinoma
- in-vitro, Oral, Ca9-22 - in-vitro, Oral, HN5
NF-kB↓, ChemoSen↑, TumCP↓, TumCD↑, Apoptosis↑,
4929- PEITC,  PacT,    Phenethyl isothiocyanate and paclitaxel synergistically enhanced apoptosis and alpha-tubulin hyperacetylation in breast cancer cells
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231
ChemoSen↑, Apoptosis↑, TumCCA↑, eff↑, CDK1↓, Bcl-2↓, BAX↑, cl‑PARP↑, SAL↑,
1436- SFN,  PacT,  docx,    Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells
- in-vivo, BC, SUM159
NF-kB↓, ChemoSen↑, IL6↓, IL8↑,

Showing Research Papers: 1 to 7 of 7

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 7

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

miR-199↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

ROS↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

MMP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

PI3K/Akt↓, 1,  

Cell Death(tgid=5) ⓘ

p‑Akt↓, 1,   Apoptosis↑, 5,   BAX↑, 3,   Bcl-2↓, 3,   Casp3↑, 3,   Casp9↑, 1,   TumCD↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

HATs↓, 1,   tumCV↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

TumAuto↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

cl‑PARP↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 1,   TumCCA↑, 3,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ERK↓, 1,   p‑ERK↓, 1,   Let-7↑, 1,   NOTCH1↓, 1,   SAL↑, 1,   STAT3↓, 1,   TumCG↓, 1,   Wnt/(β-catenin)↓, 1,  

Migration(tgid=13) ⓘ

E-cadherin↑, 1,   MMP9↓, 1,   TGF-β↓, 1,   TumCI↓, 1,   TumCP↓, 2,   Vim↓, 1,   Zeb1↓, 1,   ZEB2↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

VEGF↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,   IL6↓, 2,   IL8↑, 1,   Inflam↓, 1,   NF-kB↓, 4,   TLR4↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 7,   Dose↝, 1,   eff↓, 1,   eff↑, 1,   selectivity↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

IL6↓, 2,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   antiNeop↑, 1,   AntiTum↑, 1,   chemoP↑, 1,   ChemoSideEff∅, 1,   TumVol↓, 1,  
Total Targets: 52

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: ChemoSen, chemo-sensitization
7 Paclitaxel/Taxol
1 Emodin
1 Formononetin
1 Garcinol
1 Cisplatin
1 Hyperoside
1 IP6 (Inositol 1,2,3,4,5,6-hexakisphosphate)
1 Phenethyl isothiocyanate
1 Sulforaphane (mainly Broccoli)
1 Docetaxel
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:182  Target#:1106  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page